Promising new data for the CUROLOX® based regenerative treatment of periodontitis have been presented at the interdisciplinary BIONITERFACES congress in Zurich, Switzerland.
Especially the new in vitro perio-model, developed in collaboration with the ZHAW, FHNW and the University of Zurich gave fundamental insight into how the CUROLOX® Technology supports periodontal regeneration, and enabled the identification of the most promising candidates for the subsequent preclinical development.
“The BIOINTERFACES, taking place in Zurich between August 23-25, was an excellent platform to present our project and the research results. It was very inspiring to discuss these data with various colleagues, who in general have shown great interest in our platform and the approach with the CUROLOX® Technology”, says Dr. Stephanie Mathes, Lecturer in Tissue Engineering at the ZHAW Wädenswil, Switzerland.
About credentis ag
credentis ag is headquartered in Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNF), Aargauer Forschungsfonds and CTI in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
